Piperazine CaV3.2 Inhibitors for Selective Neuropathic Pain Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neuropathic pain, particularly those targeting the CaV3.2 voltage gated calcium channels, lack selectivity and efficacy, leading to dose limitations and ineffective clinical outcomes.

Innovation Solution

Development of a new class of small-molecule inhibitors, such as 5bk, with a piperazine or piperidine structure, that selectively target and inhibit CaV3.2 channels, reducing depolarization-induced calcium influx and associated pain, including HIV-associated and chemotherapy-induced neuropathies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If T-type Ca2+ channel blockers (e.g., ethosuximide, mibefradil, TTA-A2, TTA-P2) are used to treat neuropathic pain, then pain relief is achieved, but selectivity for CaV3.2 is insufficient leading to dose limitations

Engineering Contradiction:

Improvepain relief efficacyVSAvoidselectivity for CaV3.2

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies local quality by designing compounds with specific structural features (piperazine or piperidine core with particular substituents) that confer selective affinity for CaV3.2 channels over other T-type channel isoforms. This localized structural optimization enables the compound to target specifically the CaV3.2 channel subtype expressed in nociceptive neurons, achieving both pain relief and selectivity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations on the piperazine/piperidine core) to optimize binding affinity and selectivity for CaV3.2. Through structure-activity relationship studies, specific parameter combinations were identified that enhance CaV3.2 selectivity while maintaining therapeutic efficacy, thereby resolving the contradiction between efficacy and selectivity.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If non-selective T-type calcium channel inhibitors are administered, then some pain relief is achieved, but clinical endpoints are not met due to lack of selectivity

Engineering Contradiction:

Improveclinical efficacyVSAvoidselectivity for CaV3.2 isoform

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent applies asymmetry by introducing chiral centers and asymmetric substitution patterns on the piperazine/piperidine core. The specific (R)- or (S)-configured substituents create asymmetric molecular geometry that complements the asymmetric binding site of CaV3.2 channels, enabling stereoselective binding. This asymmetric design provides the measurement precision needed to distinguish CaV3.2 from other channel isoforms while maintaining clinical efficacy.

Inventive Principle:

Principle #4Asymmetry

3Reliability

If higher doses of non-selective blockers are used to overcome selectivity issues, then pain relief may improve, but side effects increase and therapeutic window narrows

Engineering Contradiction:

Improvepain reliefVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs the intermediary principle by designing compounds that act as selective mediators between the therapeutic goal (pain relief) and the biological target (CaV3.2 channel). The highly selective CaV3.2-blocking compounds serve as precise intermediaries that achieve pain relief through specific CaV3.2 inhibition without activating other channels or pathways, thereby avoiding the side effects associated with non-selective blockers and expanding the therapeutic window.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

5bk effectively reverses mechanical allodynia in neuropathic pain models by selectively inhibiting CaV3.2 channels without affecting locomotion or anxiety, providing a promising non-opioid therapeutic option.

Implementation Method 1

small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium channel activity (e.g., depolarization-induced calcium influx)

Methodology Applied

Scientific EffectIon channel blocking:

Data Source

PatentUS12486257B2Small molecule inhibitors of CaV3.2 activity and uses thereof

Publication Date: 2025.12.02 THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

AI summary

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium channel activity (e.g., depolarization-induced calcium influx), and their use as therapeutics for the treatment and/or prevention of CaV3.2 related pain (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) and related conditions.